Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-MarketGlobeNewsWire • 03/22/21
Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access PathwayGlobeNewsWire • 03/11/21
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021GlobeNewsWire • 02/10/21
ATOS Stock: 8 Things for Investors to Know About Atossa Therapeutics as It Soars ThursdayInvestorPlace • 02/04/21
Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with EndoxifenGlobeNewsWire • 02/03/21
Atossa Therapeutics' Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to be Halted EarlyGlobeNewsWire • 02/02/21
Atossa Therapeutics Receives $21 Million from Recent Exercises of Outstanding WarrantsGlobeNewsWire • 01/29/21
Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S.GlobeNewsWire • 01/25/21
COVID-19 Origin and Spread Linked to PLA Hospital and Wuhan Metro System Line 2 by Physician-Scientist Dr. Steven QuayPRNewsWire • 01/08/21
Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-MarketGlobeNewsWire • 01/06/21
Atossa Therapeutics Announces Pricing of $14.0 Million Registered Direct Offering Priced At-The-MarketGlobeNewsWire • 12/17/20
Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public OfferingGlobeNewsWire • 12/09/20
Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/13/20
Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19GlobeNewsWire • 11/10/20
New Research Points to the People's Liberation Army Hospital in Wuhan, China as the Origin for the Worldwide Coronavirus PandemicPRNewsWire • 10/28/20
Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVIDGlobeNewsWire • 10/19/20
Registration Is Now Open For Atossa Therapeutics’ Tribe Public Webinar Presentation and Q&A Event On October 13, 2020GlobeNewsWire • 10/07/20
Physician-Scientist Dr. Steven Quay Provides Best-Selling Book, "Stay Safe: A Physician's Guide to Survive Coronavirus," to the White House Upon the News of COVID in the First FamilyPRNewsWire • 10/02/20